Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030.
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Ethan Billings, Chief Advisor and Analyst at TD Securities in Washington, provides tailored trading strategies for a select group of high-net-worth clients. Specializing in the biotech sector, he regularly shares in-depth research reports highlighting high-quality investment opportunities. In addition, he has established a dedicated WhatsApp group for strategy discussions, where members receive timely and precise buy/sell recommendations.
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill.
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation, Chevron Corporation, and Stryker Corporation, as well as two micro-cap stocks, Value Line, Inc. and Sypris Solutions, Inc.
